

1/17





FIG. 1



Endpoints

Primary	Safety & tolerability
Secondary/ Exploratory	Pharmacokinetic measures (half-life, bioavailability)
SAD & MAD	IRAK4 knockdown in PBMC
Exploratory	Ex vivo response of whole blood to TLR agonists (SAD & MAD) and IL-1β (MAD only)
SAD & MAD	
Exploratory	IRAK4 knockdown in skin biopsies
MAD Only	- Proinflammatory cytokine and chemokine levels in skin biopsies (Patients only) - Plasma C-reactive protein (HV and Patients) and cytokine levels (Patients only)

FIG. 2

3/17




FIG. 3

4/17




FIG. 4

5/17




FIG. 5

6/17




FIG. 6




FIG. 7

8/17




FIG. 8

9/17




FIG. 8 Continued

10/17




FIG. 9

11/17




FIG. 10

12/17




FIG. 11




FIG. 12




FIG. 13

SUBSTITUTE SHEET (RULE 26)

15/17





FIG. 14

16/17






FIG. 15

17/17



Pbo	357%	292%	-5%	-10%	880%	-11%	72%	91%	70%
50 mg QD	116%	-39%	15%	-27%	4%	81%	2%	-2%	40%
100 mg QD	-48%	-63%	-54%	-46%	-49%	-42%	-28%	-58%	-57%

50mg QD: 93-95% PBMC degradation at Day 7-10; 87-90% Monocyte degradation at Day 7-14
 100mg QD: 97-98% PBMC degradation at Day 7-10; 92-93% Monocyte degradation at Day 7-14



Pbo	>500%	15%	35%	-5%	158%	3%	107%	-7%
50 mg QD	-62%	-59% ¹	-18%	-28%	2%	-58% ²	-24%	-21%
100 mg QD	-85%	-68% ¹	-53%	-32%	-50%	-72% ²	-46%	-59% ²

¹ = p - value < 0.01; ² = p - value < 0.05

FIG. 16

SUBSTITUTE SHEET (RULE 26)